Cargando…

Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities

Median arcuate ligament syndrome (MALS) is a rare constellation of neurogenic gastrointestinal (GI) symptoms resulting from compression of the celiac trunk and celiac plexus by the median arcuate ligament. MALS is characterized by nonspecific symptoms including nausea, vomiting, diarrhea, bloating,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kharbat, Abdurrahman F, Kile, Ranger, Kankam, Alfred, Galvan, Bernardo, Holder, Katherine G, Soliman, Basem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333558/
https://www.ncbi.nlm.nih.gov/pubmed/35911332
http://dx.doi.org/10.7759/cureus.26401
_version_ 1784758904146624512
author Kharbat, Abdurrahman F
Kile, Ranger
Kankam, Alfred
Galvan, Bernardo
Holder, Katherine G
Soliman, Basem
author_facet Kharbat, Abdurrahman F
Kile, Ranger
Kankam, Alfred
Galvan, Bernardo
Holder, Katherine G
Soliman, Basem
author_sort Kharbat, Abdurrahman F
collection PubMed
description Median arcuate ligament syndrome (MALS) is a rare constellation of neurogenic gastrointestinal (GI) symptoms resulting from compression of the celiac trunk and celiac plexus by the median arcuate ligament. MALS is characterized by nonspecific symptoms including nausea, vomiting, diarrhea, bloating, unintentional weight loss due to food aversion, and postprandial epigastric abdominal pain. We present a case of atypical, chronic MALS that confounded clinicians for over a decade and led to various misdiagnoses, including early-onset Parkinson’s disease. Of the constellation of symptoms that MALS may present with, postprandial epigastric pain is a classic symptom and increases the index of suspicion for the diagnosis; however, the absence of the classic symptom of postprandial epigastric pain and the predomination of nonspecific GI symptoms and syncope in our patient further clouded clinicians’ ability to diagnose MALS. Upon further investigation, we elucidated a link between gabapentin, which our patient was chronically prescribed, and its efficacy in decreasing neurogenic hypersensitivity in the GI tract. Our case and the implications of gabapentin use to decrease neurogenic pain from MALS represents a novel addition to the literature on MALS treatment modalities and elucidates new avenues for continued research in the use of gabapentin as a symptom-modifying agent in the nonoperative and preoperative treatment of MALS.
format Online
Article
Text
id pubmed-9333558
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-93335582022-07-30 Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities Kharbat, Abdurrahman F Kile, Ranger Kankam, Alfred Galvan, Bernardo Holder, Katherine G Soliman, Basem Cureus Pain Management Median arcuate ligament syndrome (MALS) is a rare constellation of neurogenic gastrointestinal (GI) symptoms resulting from compression of the celiac trunk and celiac plexus by the median arcuate ligament. MALS is characterized by nonspecific symptoms including nausea, vomiting, diarrhea, bloating, unintentional weight loss due to food aversion, and postprandial epigastric abdominal pain. We present a case of atypical, chronic MALS that confounded clinicians for over a decade and led to various misdiagnoses, including early-onset Parkinson’s disease. Of the constellation of symptoms that MALS may present with, postprandial epigastric pain is a classic symptom and increases the index of suspicion for the diagnosis; however, the absence of the classic symptom of postprandial epigastric pain and the predomination of nonspecific GI symptoms and syncope in our patient further clouded clinicians’ ability to diagnose MALS. Upon further investigation, we elucidated a link between gabapentin, which our patient was chronically prescribed, and its efficacy in decreasing neurogenic hypersensitivity in the GI tract. Our case and the implications of gabapentin use to decrease neurogenic pain from MALS represents a novel addition to the literature on MALS treatment modalities and elucidates new avenues for continued research in the use of gabapentin as a symptom-modifying agent in the nonoperative and preoperative treatment of MALS. Cureus 2022-06-28 /pmc/articles/PMC9333558/ /pubmed/35911332 http://dx.doi.org/10.7759/cureus.26401 Text en Copyright © 2022, Kharbat et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pain Management
Kharbat, Abdurrahman F
Kile, Ranger
Kankam, Alfred
Galvan, Bernardo
Holder, Katherine G
Soliman, Basem
Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities
title Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities
title_full Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities
title_fullStr Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities
title_full_unstemmed Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities
title_short Gabapentin as a Symptomatic Modifier in Median Arcuate Ligament Syndrome: A Case Report and Assessment of Treatment Modalities
title_sort gabapentin as a symptomatic modifier in median arcuate ligament syndrome: a case report and assessment of treatment modalities
topic Pain Management
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333558/
https://www.ncbi.nlm.nih.gov/pubmed/35911332
http://dx.doi.org/10.7759/cureus.26401
work_keys_str_mv AT kharbatabdurrahmanf gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities
AT kileranger gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities
AT kankamalfred gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities
AT galvanbernardo gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities
AT holderkatherineg gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities
AT solimanbasem gabapentinasasymptomaticmodifierinmedianarcuateligamentsyndromeacasereportandassessmentoftreatmentmodalities